Silmitasertib (CX-4945) is a potent and selective orally bioavailable small molecule inhibitor of Casein kinase II (CK2). The antiproliferative activity of CX-4945 against cancer cells correlated with expression levels of the CK2α catalytic subunit. CX-4945 caused cell-cycle arrest and selectively induced apoptosis in cancer cells relative to normal cells.
For research use only. We do not sell to patients.
Name | CX-4945(Silmitasertib) |
---|---|
Iupac Chemical Name | 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid |
Synonyms | CX-4945;Silmitasertib;CX4945;CX 4945 |
Molecular Formula | C19H12ClN3O2 |
Molecular Weight | 349.77 |
Smile | ClC=1C=C(C=CC1)NC1=NC2=C(C3=CN=CC=C13)C=CC(=C2)C(=O)O |
InChiKey | MUOKSQABCJCOPU-UHFFFAOYSA-N |
InChi | InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25) |
CAS Number | 1009820-21-6 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | yellow solid |
---|---|
Purity | 98% |
Storage | 3 years -20ºCpowder 6 months-80ºCin solvent |
Solubility | 5mg/ml in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |